Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 181

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 8
Chunk 181
---
 STOCKHOLDERS’ DEFICIT

    Accounts payable

    2,728,212

    3,911,973

    Accrued liabilities

    1,873,561

    5,037,361

    Other current liabilities

    2,357,903

    2,453,251

    Total current liabilities

    6,959,676

    11,402,585

    Related party note

    4,924,612

    —

    Other long-term liabilities

    —

    48,072

    Due to related parties

    13,422,407

    11,157,073

    Commitments and contingencies

    Stockholders’ deficit

    Common stock, par value $0.00001 per share, 150,000,000 shares   authorized, 3,963,045 and 3,459,910 shares issued and outstanding as of    December 31, 2024 and 2023, respectively

    40

    35

    Additional paid-in capital

    125,227,389

    115,772,396

    Accumulated other comprehensive loss

    (631,576
    )

    (430,947
    )

    Accumulated deficit

    (144,181,735
    )

    (133,396,933
    )

    Total stockholders’ deficit

    (19,585,882
    )

    (18,055,449
    )

    Total liabilities and stockholders’ deficit
     
    $
    5,720,813

    $
    4,552,281

See accompanying notes to consolidated financial statements. 

 70

MiNK THERAPEUTICS, INC. AND SUBSIDIARIES 

CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS 

    For the Year EndedDecember 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    6,336,075

    $
    15,489,997

    General and administrative

    4,314,164

    7,431,108

    Change in fair value of related party note

    638,046

    —

    Operating loss

    (11,288,285
    )

    (22,921,